WO2004029197A3 - Co-stimulatory molecules - Google Patents

Co-stimulatory molecules Download PDF

Info

Publication number
WO2004029197A3
WO2004029197A3 PCT/US2002/019898 US0219898W WO2004029197A3 WO 2004029197 A3 WO2004029197 A3 WO 2004029197A3 US 0219898 W US0219898 W US 0219898W WO 2004029197 A3 WO2004029197 A3 WO 2004029197A3
Authority
WO
WIPO (PCT)
Prior art keywords
human
polypeptides
ctla
ability
bind
Prior art date
Application number
PCT/US2002/019898
Other languages
French (fr)
Other versions
WO2004029197A2 (en
WO2004029197A8 (en
Inventor
Juha Punnonen
Alexandra L L Lazetic
Steven R Leong
Jean Chia-Chun Chang
Doris Apt
Claes Gustafsson
Original Assignee
Maxygen Inc
Juha Punnonen
Alexandra L L Lazetic
Steven R Leong
Jean Chia-Chun Chang
Doris Apt
Claes Gustafsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/888,324 external-priority patent/US7094875B2/en
Priority claimed from US10/032,214 external-priority patent/US7183376B2/en
Application filed by Maxygen Inc, Juha Punnonen, Alexandra L L Lazetic, Steven R Leong, Jean Chia-Chun Chang, Doris Apt, Claes Gustafsson filed Critical Maxygen Inc
Priority to AU2002368044A priority Critical patent/AU2002368044A1/en
Priority to EP02807658A priority patent/EP1497426A2/en
Priority to US10/479,901 priority patent/US20050154189A1/en
Publication of WO2004029197A2 publication Critical patent/WO2004029197A2/en
Publication of WO2004029197A3 publication Critical patent/WO2004029197A3/en
Publication of WO2004029197A8 publication Critical patent/WO2004029197A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a human CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind human CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynulceotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.
PCT/US2002/019898 2000-06-23 2002-06-21 Co-stimulatory molecules WO2004029197A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002368044A AU2002368044A1 (en) 2001-06-22 2002-06-21 Co-stimulatory molecules
EP02807658A EP1497426A2 (en) 2001-06-22 2002-06-21 Co-stimulatory molecules
US10/479,901 US20050154189A1 (en) 2000-06-23 2002-06-21 Novel co-stimulatory molecules

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
USPCT/US01/19973 2001-06-22
US09/888,324 2001-06-22
US09/888,324 US7094875B2 (en) 2000-06-23 2001-06-22 Co-stimulatory polypeptides
PCT/US2001/019973 WO2002000717A2 (en) 2000-06-23 2001-06-22 Novel co-stimulatory molecules
US10/032,214 2001-12-20
US10/032,214 US7183376B2 (en) 2000-06-23 2001-12-20 Variant B7 co-stimulatory molecules

Publications (3)

Publication Number Publication Date
WO2004029197A2 WO2004029197A2 (en) 2004-04-08
WO2004029197A3 true WO2004029197A3 (en) 2004-10-28
WO2004029197A8 WO2004029197A8 (en) 2005-07-21

Family

ID=56290305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019898 WO2004029197A2 (en) 2000-06-23 2002-06-21 Co-stimulatory molecules

Country Status (3)

Country Link
EP (1) EP1497426A2 (en)
AU (1) AU2002368044A1 (en)
WO (1) WO2004029197A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3640375A3 (en) 2012-12-11 2020-07-29 Albert Einstein College of Medicine Methods for high throughput receptor/ligand identification
SI3283508T1 (en) 2015-04-17 2021-09-30 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
MA43552A (en) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc CD80 VARIANT IMMUNOMODULATOR PROTEINS AND THEIR USES
CA3022331A1 (en) 2016-05-18 2017-11-23 Albert Einstein College Of Medicine, Inc. Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
SG11201808552XA (en) 2016-05-18 2018-10-30 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
IL266696B2 (en) 2016-12-22 2023-04-01 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR102619015B1 (en) 2017-03-15 2023-12-28 큐 바이오파마, 인크. How to Regulate Your Immune Response
MX2019010887A (en) 2017-03-16 2019-10-15 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof.
EP3596115A1 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
EP3628070B1 (en) 2017-04-28 2021-09-08 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides for use in increasing central memory t cells
EA202090974A1 (en) 2017-10-18 2020-08-05 Элпайн Иммьюн Сайенсиз, Инк. VARIANT IMMUNOMODULATING PROTEINS OF ICOS LIGAND AND ACCOMPANYING COMPOSITIONS AND METHODS
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN112673093A (en) * 2018-07-04 2021-04-16 赛通免疫治疗公司 Compositions and methods for immunotherapy targeting FLT3, PD-1, and/or PD-L1
MA53651A (en) * 2018-09-19 2021-07-28 Alpine Immune Sciences Inc METHODS AND USES OF CD80 VARIANT FUSION PROTEINS AND RELATED CONSTRUCTIONS
TW202208395A (en) 2020-05-12 2022-03-01 美商信號生物製藥公司 Multimeric t-cell modulatory polypeptides and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018204A1 (en) * 1999-09-03 2001-03-15 Curagen Corporation Polynucleotides encoding members of the human b lymphocyte activation antigen b7 family and polypeptides encoded thereby
WO2002000717A2 (en) * 2000-06-23 2002-01-03 Maxygen, Inc. Novel co-stimulatory molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018204A1 (en) * 1999-09-03 2001-03-15 Curagen Corporation Polynucleotides encoding members of the human b lymphocyte activation antigen b7 family and polypeptides encoded thereby
WO2002000717A2 (en) * 2000-06-23 2002-01-03 Maxygen, Inc. Novel co-stimulatory molecules

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CRAMERI A ET AL: "DNA SHUFFLING OF A FAMILY OF GENES FROM DIVERSE SPECIES ACCELERATESDIRECTED EVOLUTION", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 391, 15 January 1998 (1998-01-15), pages 288 - 291, XP000775869, ISSN: 0028-0836 *
DATABASE EMBL [online] 9 December 1997 (1997-12-09), XP002290883, retrieved from EBI Database accession no. Y09950 *
FARGEAS C A ET AL: "IDENTIFICATION OF RESIDUES IN THE V DOMAIN OF CD80 (B7-1) IMPLICATED IN FUNCTIONAL INTERACTIONS WITH CD28 AND CTLA4", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 182, 1 September 1995 (1995-09-01), pages 667 - 675, XP002912153, ISSN: 0022-1007 *
GUO Y ET AL: "MUTATIONAL ANALYSIS AND AN ALTERNATIVELY SPLICED PRODUCT OF B7 DEFINES ITS CD28/CTLA4-BINDING SITE ON IMMUNOGLOBULIN C-LIKE DOMAIN", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 181, no. 4, 1 April 1995 (1995-04-01), pages 1345 - 1355, XP002018930, ISSN: 0022-1007 *
LAZETIC S ET AL: "Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 277, no. 41, 11 October 2002 (2002-10-11), pages 38660 - 38668, XP002231015, ISSN: 0021-9258 *
PARSONS K R ET AL: "Cloning of cattle CD80", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 49, 1999, pages 231 - 234, XP002231013, ISSN: 0093-7711 *
PEACH R J ET AL: "BOTH EXTRACELLULAR IMMUNOGLOBIN-LIKE DOMAINS OF CD80 CONTAIN RESIDUES CRITICAL FOR BINDINGT CELL SURFACE RECEPTORS CTLA-4 AND CD28", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 270, no. 36, 8 September 1995 (1995-09-08), pages 21181 - 21187, XP002912152, ISSN: 0021-9258 *
STEMMER W P C: "Rapid evolution of a protein in vitro by DNA shuffling", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 370, 4 August 1994 (1994-08-04), pages 389 - 391, XP002082182, ISSN: 0028-0836 *
WORARATANADHARM J ET AL: "Creation of novel costimulatory ligands through directed molecular evolution", TRENDS IN IMMUNOLOGY, ELSEVIER, CAMBRIDGE, GB, vol. 23, no. 12, 1 December 2002 (2002-12-01), pages 568 - 569, XP004395657, ISSN: 1471-4906 *

Also Published As

Publication number Publication date
WO2004029197A2 (en) 2004-04-08
AU2002368044A1 (en) 2004-04-19
EP1497426A2 (en) 2005-01-19
AU2002368044A8 (en) 2004-04-19
WO2004029197A8 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
WO2002000717A3 (en) Novel co-stimulatory molecules
WO2004029197A8 (en) Co-stimulatory molecules
WO2000072742A3 (en) Methods and materials for generating sh3 domains with tailored binding properties
WO2000023955A8 (en) Virus-like particles for the induction of autoantibodies
WO2003083041A3 (en) Cripto-specific antibodies
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2001000244A3 (en) METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
WO2002088170A3 (en) Cripto blocking antibodies and uses thereof
EP1918300A3 (en) Peptide-based immunization therapy for treatment of atherosclerosis
WO2004007553A8 (en) Antibodies anti-c5 component of the complement system and their use
WO2002074156A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003082212A3 (en) Method for treating cancer in humans
WO2003013535A3 (en) Use of irinotecan for improved treatment of cancer based on mdr1
WO2003018758A3 (en) Reagents and methods for smooth muscle therapies
WO2005123908A3 (en) Novel cancer cell lines and uses thereof
WO2002078614A3 (en) Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO2004083404A3 (en) Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain
WO1998059040A3 (en) Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
IL158159A0 (en) NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNalpha-21 GENE
WO2004035799A3 (en) Viral vectors and the use of the same for gene therapy
WO2005011725A3 (en) Anti-angiogenetic agent and its use, in particular in cancer treatment
WO2002058724A3 (en) Use of lp82 to treat body weight disorders
WO2004031354A3 (en) Human sarcoma-associated antigens
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2002807658

Country of ref document: EP

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10479901

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002807658

Country of ref document: EP

WSNC Later publication of a supplementary international search report together with a suppl. search report established by non-competent authority
WWW Wipo information: withdrawn in national office

Ref document number: 2002807658

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP